The IPKat

NOVEMBER 14, 2022

(a wise cat that care about environment kindly provided in CC0 Public Domain license by Pixhere.com) Having to make a selection among the many topics covered, this GuestKat finds it interesting to note that during the conference the EPO case G2/21 on 'plausibility', was repeatedly discussed from different angles.

IP 76

IP Marketing Marketing Confidentiality 76

Patently-O

SEPTEMBER 26, 2022

Topics: Enablement / Written Description (All three are biotech / pharma): 3 Cases; Infringement (FDA Labeling): 1 Case; Anticipation (On Sale Bar): 1 Case; Double Patenting (Still the law?) Mylan Pharmaceuticals Inc. , Skinny Label Infringement in Teva Pharmaceuticals USA, Inc. GlaxoSmithKline LLC , No.

Patent Law 126

Patent Law Law Patent Invention 126

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

Herzuma ® (Celltrion/ Teva). Truxima ® (Celltrion/Teva). The letter discusses the BPCIA and the Hatch-Waxman Act frameworks (for small molecule drugs) and sets forth several topics for USPTO’s consideration and further discussion: engagement between FDA and USPTO to increase efficiencies, possible misuse of the patent system (e.g.,

Litigation 52

Litigation Settlement Patent Marketing 52